PMID- 38247494
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240128
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 13
IP  - 1
DP  - 2024 Jan 2
TI  - The Multifaceted Roles of NRF2 in Cancer: Friend or Foe?
LID - 10.3390/antiox13010070 [doi]
LID - 70
AB  - Physiological concentrations of reactive oxygen species (ROS) play vital roles in 
      various normal cellular processes, whereas excessive ROS generation is central to 
      disease pathogenesis. The nuclear factor erythroid 2-related factor 2 (NRF2) is a 
      critical transcription factor that regulates the cellular antioxidant systems in 
      response to oxidative stress by governing the expression of genes encoding 
      antioxidant enzymes that shield cells from diverse oxidative alterations. NRF2 
      and its negative regulator Kelch-like ECH-associated protein 1 (KEAP1) have been 
      the focus of numerous investigations in elucidating whether NRF2 suppresses tumor 
      promotion or conversely exerts pro-oncogenic effects. NRF2 has been found to 
      participate in various pathological processes, including dysregulated cell 
      proliferation, metabolic remodeling, and resistance to apoptosis. Herein, this 
      review article will examine the intriguing role of phase separation in activating 
      the NRF2 transcriptional activity and explore the NRF2 dual impacts on tumor 
      immunology, cancer stem cells, metastasis, and long non-coding RNAs (LncRNAs). 
      Taken together, this review aims to discuss the NRF2 multifaceted roles in both 
      cancer prevention and promotion while also addressing the advantages, 
      disadvantages, and limitations associated with modulating NRF2 therapeutically in 
      cancer treatment.
FAU - Glorieux, Christophe
AU  - Glorieux C
AUID- ORCID: 0000-0003-1944-611X
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Enriquez, Cinthya
AU  - Enriquez C
AUID- ORCID: 0000-0002-9839-7389
AD  - Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, 
      Iquique 1100000, Chile.
AD  - Programa de Magister en Ciencias Quimicas y Farmaceuticas, Facultad de Ciencias 
      de la Salud, Universidad Arturo Prat, Iquique 1100000, Chile.
FAU - Gonzalez, Constanza
AU  - Gonzalez C
AD  - Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, 
      Iquique 1100000, Chile.
FAU - Aguirre-Martinez, Gabriela
AU  - Aguirre-Martinez G
AUID- ORCID: 0000-0002-0981-7434
AD  - Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, 
      Iquique 1100000, Chile.
AD  - Instituto de Quimica Medicinal, Universidad Arturo Prat, Iquique 1100000, Chile.
FAU - Buc Calderon, Pedro
AU  - Buc Calderon P
AD  - Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, 
      Iquique 1100000, Chile.
AD  - Instituto de Quimica Medicinal, Universidad Arturo Prat, Iquique 1100000, Chile.
AD  - Research Group in Metabolism and Nutrition, Louvain Drug Research Institute, 
      Universite Catholique de Louvain, 1200 Brussels, Belgium.
LA  - eng
GR  - 1190577/Fondo Nacional de Ciencia y Tecnologia (FONDECYT, Chile)/
PT  - Journal Article
PT  - Review
DEP - 20240102
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC10812565
OTO - NOTNLM
OT  - LncRNA
OT  - NRF2
OT  - NRF2 activators
OT  - NRF2 inhibitors
OT  - cancer
OT  - metabolism
OT  - metastasis
OT  - natural compounds
OT  - phase separation
OT  - tumor immunology
COIS- The authors declare no conflicts of interest.
EDAT- 2024/01/22 06:42
MHDA- 2024/01/22 06:43
PMCR- 2024/01/02
CRDT- 2024/01/22 04:23
PHST- 2023/12/06 00:00 [received]
PHST- 2023/12/21 00:00 [revised]
PHST- 2023/12/29 00:00 [accepted]
PHST- 2024/01/22 06:43 [medline]
PHST- 2024/01/22 06:42 [pubmed]
PHST- 2024/01/22 04:23 [entrez]
PHST- 2024/01/02 00:00 [pmc-release]
AID - antiox13010070 [pii]
AID - antioxidants-13-00070 [pii]
AID - 10.3390/antiox13010070 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2024 Jan 2;13(1):70. doi: 10.3390/antiox13010070.